MHRA-100268-PIP01-21-M03 (update)

Key Facts

PIPS Key Facts
Active Substance
Active Substance:
Invented Name
  • Besponsa
  • Besponsa
PIP Number MHRA-100268-PIP01-21-M03 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Powder for concentrate for solution for infusion
Therapeutic area
  • Haematology-Hemostaseology
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of B cell acute lymphoblastic leukaemia
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):INOTUZUMAB OZOGAMICIN.pdf
Published Date 24/08/2023